Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy : Results of the Randomized FOCUS4-N Trial

Adams, R A, Fisher, D J, Graham, J, Seligmann, J F, Seymour, M, Kaplan, R, Yates, E, Parmar, M, Richman, S D, Quirke, P, Butler, R, Brown, E, Collinson, F, Falk, S, Wasan, H, Shiu, K-K, Middleton, G, Samuel, L, Wilson, R H, Brown, L C, Maughan, T S & FOCUS Trial Collaboration 2021, 'Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy : Results of the Randomized FOCUS4-N Trial', Journal of Clinical Oncology, vol. 39, no. 33, JCO.21.01436, pp. 3693-3704. https://doi.org/10.1200/JCO.21.01436